Baxter Expects To Roughly Double Renal Business By 2005 To $3.5 Bil.
This article was originally published in The Gray Sheet
Executive Summary
Baxter says it plans to approximately double the size of its renal business to $3.5 bil. annually by 2005, from $1.8 bil. in 2000, increasing the unit's annual growth rate to about 15% over the next several years from the current 9% level, the firm says.